青光眼治疗市场－全球产业规模、份额、趋势、机会和预测，依治疗类型、青光眼类型、地区和竞争格局划分，2020-2030年预测

2024年全球青光眼治疗市场规模为73.3亿美元，预计2030年将以6.57%的复合年增长率成长至107.4亿美元。全球青光眼治疗市场涵盖旨在降低眼内压和预防视神经损伤的药物和手术干预措施，从而保护青光眼患者的视力。推动市场成长的关键因素包括全球青光眼盛行率的上升和老年人口的不断增长。

主要市场驱动因素

全球老年人口的成长代表着人口结构的根本转变，对青光眼治疗市场产生了显着影响。随着年龄的增长，个体患青光眼的风险显着增加，因此，人口老化是推动患者数量增长的主要因素。

主要市场挑战

患者长期用药依从性差是全球青光眼治疗市场扩张的一大障碍。青光眼药物治疗的疗效从根本上取决于患者能否持续、及时地坚持用药，从而有效降低眼压，并防止视神经损伤加重。

主要市场趋势

将人工智慧应用于青光眼诊断和治疗代表着一种变革性趋势，它提高了患者护理的精确度和效率。人工智慧演算法可以分析复杂的眼科影像和临床资料，从而促进疾病的早期发现和更准确的病情进展监测，进而实现及时介入。

目录

第一章：产品概述

第二章：研究方法

第三章：执行概要

第四章：顾客之声

第五章：全球青光眼治疗市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依治疗类型（眼药水、药物、雷射手术、传统手术）
  • 依青光眼类型（开角型、闭角型）
  • 按地区
  • 按公司（2024 年）
• 市场地图

第六章：北美青光眼治疗市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲青光眼治疗市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区青光眼治疗市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲青光眼治疗市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿联酋
  • 南非

第十章：南美洲青光眼治疗市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章：市场动态

• 司机
• 挑战

第十二章：市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章：全球青光眼治疗市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商议价能力
• 顾客的力量
• 替代产品的威胁

第十五章：竞争格局

• Novartis AG
• Merck & Co., Inc.
• AbbVie, Inc.
• Bausch Health Companies, Inc.
• Teva Pharmaceutical Industries Ltd.
• Pfizer Inc.
• Alcon, Inc.
• Inotek Pharmaceuticals Corporation

第十六章：策略建议

第17章调查会社について・免责事项

The Global Glaucoma Therapeutics Market , valued at USD 7.33 Billion in 2024, is projected to experience a CAGR of 6.57% to reach USD 10.74 Billion by 2030. The global glaucoma therapeutics market encompasses pharmacological and surgical interventions designed to reduce intraocular pressure and prevent optic nerve damage, thereby preserving vision in individuals diagnosed with glaucoma. Key drivers supporting market growth include the rising global prevalence of glaucoma and the expanding geriatric population.

Key Market Drivers

The increasing global geriatric population represents a fundamental demographic shift significantly influencing the glaucoma therapeutics market. As individuals age, their susceptibility to developing glaucoma rises substantially, making this demographic expansion a primary driver of increased patient volumes. Older age is a well-established risk factor for glaucoma onset and progression, directly translating to a greater need for diagnostic screenings and subsequent therapeutic interventions.

Key Market Challenges

Patient non-adherence to long-term medication regimens presents a substantial impediment to the expansion of the global glaucoma therapeutics market. The efficacy of pharmacological interventions for glaucoma is fundamentally dependent on consistent and timely patient compliance to effectively reduce intraocular pressure and avert progressive optic nerve damage. When individuals do not adhere to their prescribed treatment schedules, the disease often progresses unchecked, leading to a greater need for more advanced and often expensive surgical procedures or a shift to alternative, more complex drug therapies. This undermines the overall perceived value and effectiveness of current pharmaceutical offerings and disrupts the consistent demand for long-term medication supplies.

Key Market Trends

The integration of artificial intelligence in glaucoma diagnostics and management represents a transformative trend, enhancing the precision and efficiency of patient care. AI algorithms can analyze complex ophthalmic imaging and clinical data to facilitate earlier disease detection and more accurate progression monitoring, thereby enabling timely interventions.

Key Market Players

• Novartis AG
• Merck & Co., Inc.
• AbbVie, Inc.
• Bausch Health Companies, Inc.
• Teva Pharmaceutical Industries Ltd.
• Pfizer Inc.
• Alcon, Inc.
• Inotek Pharmaceuticals Corporation

Report Scope:

In this report, the Global Glaucoma Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Glaucoma Therapeutics Market , By Treatment Type:

• Eye drops
• Medication
• Laser Surgery
• Traditional Surgery

Glaucoma Therapeutics Market , By Glaucoma Type:

• Open angle
• Closed angle

Glaucoma Therapeutics Market , By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Glaucoma Therapeutics Market .

Available Customizations:

Global Glaucoma Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Glaucoma Therapeutics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Treatment Type (Eye drops, Medication, Laser Surgery, Traditional Surgery)
  • 5.2.2. By Glaucoma Type (Open angle, Closed angle)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Glaucoma Therapeutics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Treatment Type
  • 6.2.2. By Glaucoma Type
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Glaucoma Therapeutics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Treatment Type
      • 6.3.1.2.2. By Glaucoma Type
  • 6.3.2. Canada Glaucoma Therapeutics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Treatment Type
      • 6.3.2.2.2. By Glaucoma Type
  • 6.3.3. Mexico Glaucoma Therapeutics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Treatment Type
      • 6.3.3.2.2. By Glaucoma Type

7. Europe Glaucoma Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Treatment Type
  • 7.2.2. By Glaucoma Type
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Glaucoma Therapeutics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Treatment Type
      • 7.3.1.2.2. By Glaucoma Type
  • 7.3.2. France Glaucoma Therapeutics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Treatment Type
      • 7.3.2.2.2. By Glaucoma Type
  • 7.3.3. United Kingdom Glaucoma Therapeutics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Treatment Type
      • 7.3.3.2.2. By Glaucoma Type
  • 7.3.4. Italy Glaucoma Therapeutics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Treatment Type
      • 7.3.4.2.2. By Glaucoma Type
  • 7.3.5. Spain Glaucoma Therapeutics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Treatment Type
      • 7.3.5.2.2. By Glaucoma Type

8. Asia Pacific Glaucoma Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Treatment Type
  • 8.2.2. By Glaucoma Type
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Glaucoma Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Treatment Type
      • 8.3.1.2.2. By Glaucoma Type
  • 8.3.2. India Glaucoma Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Treatment Type
      • 8.3.2.2.2. By Glaucoma Type
  • 8.3.3. Japan Glaucoma Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Treatment Type
      • 8.3.3.2.2. By Glaucoma Type
  • 8.3.4. South Korea Glaucoma Therapeutics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Treatment Type
      • 8.3.4.2.2. By Glaucoma Type
  • 8.3.5. Australia Glaucoma Therapeutics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Treatment Type
      • 8.3.5.2.2. By Glaucoma Type

9. Middle East & Africa Glaucoma Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Treatment Type
  • 9.2.2. By Glaucoma Type
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Glaucoma Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Treatment Type
      • 9.3.1.2.2. By Glaucoma Type
  • 9.3.2. UAE Glaucoma Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Treatment Type
      • 9.3.2.2.2. By Glaucoma Type
  • 9.3.3. South Africa Glaucoma Therapeutics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Treatment Type
      • 9.3.3.2.2. By Glaucoma Type

10. South America Glaucoma Therapeutics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Treatment Type
  • 10.2.2. By Glaucoma Type
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Glaucoma Therapeutics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Treatment Type
      • 10.3.1.2.2. By Glaucoma Type
  • 10.3.2. Colombia Glaucoma Therapeutics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Treatment Type
      • 10.3.2.2.2. By Glaucoma Type
  • 10.3.3. Argentina Glaucoma Therapeutics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Treatment Type
      • 10.3.3.2.2. By Glaucoma Type

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Glaucoma Therapeutics Market : SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Novartis AG
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Merck & Co., Inc.
• 15.3. AbbVie, Inc.
• 15.4. Bausch Health Companies, Inc.
• 15.5. Teva Pharmaceutical Industries Ltd.
• 15.6. Pfizer Inc.
• 15.7. Alcon, Inc.
• 15.8. Inotek Pharmaceuticals Corporation

16. Strategic Recommendations

17. About Us & Disclaimer